The management of chronic hepatitis B in Asian Americans

Digestive Diseases and Sciences

Volumn 56, Issue 11, 2011, Pages 3143-3162

  Tong, Myron J ^a,b   Pan, Calvin Q ^c   Hann, Hie Won ^d   Kowdley, Kris V ^e   Han, Steven Huy B ^a   Min, Albert D ^f   Leduc, Truong Sinh ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HUNTINGTON MEDICAL RESEARCH INSTITUTES   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e VIRGINIA MASON MEDICAL CENTER   (United States)

^f BETH ISRAEL MEDICAL CENTER   (United States)

^g Leduc Medical Group   (United States)

Author keywords

Antiviral therapy; Clinical features; Hepatitis B

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALBINTERFERON ALPHA2B; ALBUMIN; ALPHA FETOPROTEIN; EMTRICITABINE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; RIBAVIRIN; TELBIVUDINE; TENOFOVIR; VIRUS ANTIBODY; VIRUS DNA;

ALBUMIN BLOOD LEVEL; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; ASIAN AMERICAN; CAMBODIA; CHINA; CHRONIC HEPATITIS; CLINICAL FEATURE; CONSENSUS; DISEASE COURSE; DISEASE SURVEILLANCE; DRUG APPROVAL; DRUG EFFICACY; DRUG RESISTANCE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; END STAGE LIVER DISEASE; GENE DOSAGE; GENOTYPE; HEPATITIS B; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMIGRANT; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INDIA; INDONESIA; JAPAN; KIDNEY FUNCTION TEST; KOREA; LAOS; LIFE CYCLE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FIBROSIS; MALAYSIA; META ANALYSIS (TOPIC); MIXED INFECTION; MONOTHERAPY; MORTALITY; MULTIDRUG RESISTANCE; OUTCOME ASSESSMENT; PATIENT MONITORING; PERINATAL PERIOD; PHILIPPINES; PHYSICIAN; PRACTICE GUIDELINE; PREGNANT WOMAN; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RECURRENCE RISK; REMISSION; RISK FACTOR; SEROCONVERSION; SEXUAL TRANSMISSION; SURVIVAL; THAILAND; THROMBOCYTE COUNT; THYROID FUNCTION TEST; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; ULTRASOUND; UNITED STATES; VIET NAM; VIREMIA; VIRUS CARRIER; VIRUS LOAD; VIRUS MUTANT; VIRUS MUTATION; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; ASIAN AMERICANS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; DRUG RESISTANCE, VIRAL; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; POPULATION SURVEILLANCE;

EID: 82555197955     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-011-1841-5     Document Type: Article

References (154)

1. CK Hui N Leung ST Yuen, et al. 2007 Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase Hepatology 46 395 401 17628874 (Pubitemid 47344774)
2. I Merican R Guan D Amarapuka, et al. 2000 Chronic hepatitis B virus infection in Asian countries J Gastroenterol Hepatol 15 1356 1361 11197043 1:STN:280:DC%2BD3M7jvFCitw%3D%3D (Pubitemid 32052906)
3. GK Lau CL Lai PC Wu 1997 The natural history of chronic hepatitis B infection Hong Kong Med J 3 283 288 11847373
4. FS Yeh MC Yu CC Mo S Luo MJ Tong BE Henderson 1989 Hepatitis B virus, aflatoxins, and hepatocellular carcinoma in southern Guangxi, China Cancer Res 49 2506 2509 2539905 1:STN:280:DyaL1M3gvVGktQ%3D%3D (Pubitemid 19125586)
5. X Liang S Bi W Yang, et al. 2009 Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination Vaccine 27 6550 6557 19729084
6. HB Chae JH Kim JK Kim HJ Yim 2009 Current status of liver diseases in Korea: hepatitis B Korean J Hepatol 15 S13 S24 20037275
7. NH Park YH Chung HS Lee 2010 Impacts of vaccination on hepatitis B viral infections in Korea over a 25-year period Intervirology 53 20 28 20068337
8. CL Lin JH Kao 2008 Hepatitis B viral factors and clinical outcomes of chronic hepatitis B J Biomed Sci 15 137 145 18058038
9. S Iino 2002 Natural history of hepatitis B and C virus infections Oncology 62 18 23 11868779 (Pubitemid 34702015)
10. HW Hann CY Kim WT London P Whitford BS Blumberg 1982 Hepatitis B virus and primary hepatocellular carcinoma: family studies in Korea Int J Cancer 30 47 51 6288579 1:STN:280:DyaL3s%2FgsF2htg%3D%3D (Pubitemid 12044234)
11. MF Yuen JL Hou A Chutaputti 2009 Hepatocellular carcinoma in the Asia-Pacific region J Gastroenterol Hepatol 24 346 353 19220670
12. MJ Tong SJ Hwang 1994 Hepatitis B virus infection in Asian Americans Gastroenterol Clin North Am 23 523 536 7989093 1:STN:280:DyaK2M%2FotVyhug%3D%3D (Pubitemid 24283697)
13. Welch S, Chiang B, Shadday P, Brosgart CL. Estimated prevalence of chronic hepatitis B (CHB) in foreign born (FB) persons living in the United States (U.S.) by country/region of origin. Presented at 59th Annual Meeting of the American Association for the Study of Liver Diseases; October 31-November 4, 2008. San Francisco, CA; 2008: Poster number 853.
14. Weinbaum CM, Williams I, Mast EE, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 2008;57:1-20.
15. RP Beasley LY Hwang 1984 Hepatocellular carcinoma and hepatitis B virus Semin Liver Dis 4 113 121 6087457 1:STN:280:DyaL2c3nsVCgtg%3D%3D
16. RD Burk LY Hwang GY Ho DA Shafritz RP Beasley 1994 Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load J Infect Dis 170 1418 1423 7995980 1:STN:280:DyaK2M%2FovVChsw%3D%3D (Pubitemid 24369900)
17. World Health Organization. Hepatitis B. Department of Communicable Diseases Surveillance and Response. www.who.int/csr/disease/hepatitis/ HepatitisB/-whocdscsrlyo2002-2.pdf ; Accessed April 13, 2011.
18. World Health Organization. Hepatitis fact sheet WHO/204, revised August, 2008. www.who.int/mediacentre/factsheets/fs204/en ; Accessed June 4, 2008.
19. CW Shepard EP Simard L Finelli AE Fiore BP Bell 2006 Hepatitis B virus infection: epidemiology and vaccination Epidemiol Rev 28 112 125 16754644 (Pubitemid 44289094)
20. G Fattovich T Stroffolini I Zagni F Donato 2004 Hepatocellular carcinoma in cirrhosis: incidence and risk factors Gastroenterology 127 S35 S50 15508101
21. KH Han SH Ahn 2005 How to predict HCC development in patients with chronic B viral liver disease? Intervirology 48 23 28 15785086 (Pubitemid 40529207)
22. CL Lin LY Liao CJ Liu, et al. 2007 Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels Hepatology 45 1193 1198 17464993 1:CAS:528:DC%2BD2sXlslOju7o%3D
23. SK Sharma N Saini Y Chwla 2005 Hepatitis B virus: inactive carriers Virol J 2 82 16191199
24. JH Hoofnagle E Doo TJ Liang R Fleischer AS Lok 2007 Management of hepatitis B: summary of a clinical research workshop Hepatology 45 1056 1075 17393513 1:CAS:528:DC%2BD2sXltlWitb0%3D (Pubitemid 46646501)
25. Marcellin P, Piratvisuth T, Brunetto M, et al. Increasing rates of HBsAG clearance and seroconversion in patients with HBeAG-negative disease treated with peginterferon Alfa-2A ± lamivudine: results of 5-year post-treatment follow up. Presented at the 44th Annual Meeting of the European Association for the Study of the Liver, April 22-26 2009. Abstract no. 805; 2009.
26. RG Gish TT Chang CL Lai, et al. 2010 Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B J Viral Hepat 17 16 22 19622117 1:STN:280:DC%2BC3c%2FhtVGnsg%3D%3D
27. EJ Heathcote P Marcellin M Buti, et al. 2011 Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B Gastroenterology 140 132 143 20955704 1:CAS:528:DC%2BC3cXhsFyltLvF
28. Heathcote EJ, Gane E, de Man R, et al. Long-term (4 year) efficacy and safety of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-positive patients (HBeAg+) with chronic hepatitis B (study 103): preliminary analysis. Presented at the 61st Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA; 2010. Abstract number 477.
29. TI Huo JC Wu PC Lee, et al. 1998 Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis Hepatology 28 231 236 9657117 1:CAS:528:DyaK1cXks1aqtrw%3D
30. MJ Tong L Hsu C Hsien, et al. 2010 A comparison of hepatitis B viral markers of patients in different clinical stages of chronic infection Hepatol Int 4 516 522 20827410
31. LA Moyer EE Mast 1994 Hepatitis B: virology, epidemiology, disease, and prevention, and an overview of viral hepatitis Am J Prev Med 10 45 55 7841006 (Pubitemid 24325976)
32. RP Perrillo T Wright J Rakela, et al. 2001 A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B Hepatology 33 424 432 11172345 1:CAS:528:DC%2BD3MXht1agtbY%3D (Pubitemid 32119032)
33. X Lin NJ Robinson M Thursz, et al. 2005 Chronic hepatitis B virus infection in the Asia-Pacific region and Africa: review of disease progression J Gastroenterol Hepatol 20 833 843 15946129 (Pubitemid 40897163)
34. CM Chu 2000 Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma J Gastroenterol Hepatol 15 E25 E30 10921378
35. CY Kim JO Kim HS Lee YB Yoon IS Song 1994 Natural course and survival of chronic hepatitis B and liver cirrhosis in Korea: observation of 20 years Korean J Med 46 217 229
36. MF Yuen HJ Yuan DK Wong, et al. 2005 Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications Gut 54 1610 1614 15871997 (Pubitemid 41531781)
37. CM Chu YF Liaw 2006 Hepatitis B virus-related cirrhosis: natural history and treatment Semin Liver Dis 26 142 152 16673292 1:CAS:528:DC%2BD28Xltlegsr8%3D
38. MJ Tong C Hsien JJ Song, et al. 2009 Factors associated with progression to hepatocellular carcinoma and to death from liver complications in patients with HBsAg-positive cirrhosis Dig Dis Sci 54 1337 1346 19242792 1:CAS:528:DC%2BD1MXlsFKrtbk%3D
39. GC Wu WP Zhou YR Zhao, et al. 2003 The natural history of chronic hepatitis B: a retrospective study Hepatobiliary Pancreat Dis Int 2 566 570 14627521
40. HI Yang SN Lu YF Liaw, et al. 2002 Hepatitis B e antigen and the risk of hepatocellular carcinoma N Engl J Med 347 168 174 12124405 1:CAS:528: DC%2BD38Xlt12jsLw%3D
41. CJ Chen HI Yang 2011 Natural history of chronic hepatitis B REVEALed J Gastroenterol Hepatol 26 628 638 21323729
42. HL Chan AY Hui ML Wong, et al. 2004 Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma Gut 53 1494 1498 15361502 (Pubitemid 39265273)
43. CJ Liu BF Chen PJ Chen, et al. 2006 Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers J Infect Dis 193 1258 1265 16586363 1:CAS:528:DC%2BD28Xkslanu7k%3D
44. JH Kao PJ Chen MY Lai DS Chen 2003 Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers Gastroenterology 124 327 334 12557138 1:CAS:528:DC%2BD3sXhsFOhtbk%3D
45. MJ Tong LM Blatt JH Kao JT Cheng WG Corey 2007 Basal core promoter T1762/A1764 and precore A1896 gene mutations in hepatitis B surface antigen-positive hepatocellular carcinoma: a comparison with chronic carriers Liver Int 27 1356 1363 17900245 1:CAS:528:DC%2BD1cXkvVGjtA%3D%3D (Pubitemid 350142249)
46. UH Iloeje HI Yang J Su CL Jen SL You CJ Chen 2006 Predicting cirrhosis risk based on the level of circulating hepatitis B viral load Gastroenterology 130 678 686 16530509 (Pubitemid 43374518)
47. CJ Chen HI Yang J Su, et al. 2006 Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level JAMA 295 65 73 16391218 1:CAS:528:DC%2BD28XhtlKqtQ%3D%3D (Pubitemid 43042691)
48. MF Yuen Y Tanaka N Shinkai, et al. 2008 Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels Gut 57 98 102 17483190 1:CAS:528:DC%2BD1cXitVKqt78%3D
49. HL Chan J Jia 2011 Chronic hepatitis B in Asia-new insights from the past decade J Gastroenterol Hepatol 26 131 137 21199524
50. ZL Fang J Yang X Ge, et al. 2002 Core promoter mutations (A(1762)T and G(1764)A) and viral genotype in chronic hepatitis B and hepatocellular carcinoma in Guangxi, China J Med Virol 68 33 40 12210428 1:CAS:528:DC%2BD38XmsFahsbc%3D (Pubitemid 34827169)
51. MF Yuen Y Tanaka M Mizokami, et al. 2004 Role of hepatitis B virus genotypes Ba and C, core promoter and precore mutations on hepatocellular carcinoma: a case control study Carcinogenesis 25 1593 1598 15090469 1:CAS:528:DC%2BD2cXntFahsr0%3D (Pubitemid 39214301)
52. BJ McMahon 2009 The natural history of chronic hepatitis B virus infection Hepatology 49 S45 S55 19399792 1:CAS:528:DC%2BD1MXlvFKqsL8%3D
53. RP Beasley LY Hwang CC Lin CS Chien 1981 Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan Lancet 2 1129 1133 6118576 1:STN:280:DyaL38%2FnvFGktg%3D%3D
54. YF Liaw N Leung JH Kao, et al. 2008 Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update Hepatol Int 2 263 283 19669255
55. MF Yuen Y Tanaka DY Fong, et al. 2009 Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B J Hepatol 50 80 88 18977053
56. BK Park YN Park SH Ahn, et al. 2007 Long-term outcome of chronic hepatitis B based on histological grade and stage J Gastroenterol Hepatol 22 383 388 17295771 1:CAS:528:DC%2BD2sXksFKntrk%3D (Pubitemid 46238769)
57. MJ Tong LM Blatt JH Kao JT Cheng WG Corey 2006 Precore/basal core promoter mutants and hepatitis B viral DNA levels as predictors for liver deaths and hepatocellular carcinoma World J Gastroenterol 12 6620 6626 17075974 1:CAS:528:DC%2BD2sXntVahs7o%3D (Pubitemid 44794938)
58. BH Zhang BH Yang ZY Tang 2004 Randomized controlled trial of screening for hepatocellular carcinoma J Cancer Res Clin Oncol 130 417 422 15042359
59. GL Wong VW Wong GM Tan, et al. 2008 Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis Liver Int Official J Int Assoc Study Liver 28 79 87 1:CAS:528:DC%2BD1cXisl2rsLw%3D
60. MJ Tong HE Sun C Hsien DS Lu 2010 Surveillance for hepatocellular carcinoma improves survival in Asian American patients with hepatitis B: results from a community-based clinic Dig Dis Sci 55 826 835 19960258
61. AC McClune MJ Tong 2010 Chronic hepatitis B and hepatocellular carcinoma Clin Liver Dis 14 461 476 20638025
62. MJ Tong MO Nguyen LT Tong LM Blatt 2009 Development of hepatocellular carcinoma after seroclearance of hepatitis B surface antigen Clin Gastroenterol Hepatol 7 889 893 19394445 1:CAS:528:DC%2BD1MXht1KitLnO
63. MF Chen HP Tsai LB Jeng, et al. 2003 Prognostic factors after resection for hepatocellular carcinoma in noncirrhotic livers: univariate and multivariate analysis World J Surg 27 443 447 12658490
64. Chang CH, Chau GY, Lui WY, Tsay SH, King KL, Wu CW. Long-term results of hepatic resection for hepatocellular carcinoma originating from the noncirrhotic liver. Arch Surg. 2004;139:320-325; discussion 326.
65. MJ Tong D Chavalitdhamrong DS Lu, et al. 2010 Survival in Asian Americans after treatments for hepatocellular carcinoma: a seven-year experience at UCLA J Clin Gastroenterol 44 e63 e70 19745756
66. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol. 2008;6:1315-1341; quiz 1286.
67. Marcellin P, Dusheiko G, Zoulim F, et al. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227-242.
68. AS Lok BJ McMahon 2009 Chronic hepatitis B: update 2009 Hepatology 50 661 662 19714720
69. MJ Tong C Hsien L Hsu HE Sun LM Blatt 2008 Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States Hepatology 48 1070 1078 18688879
70. MJ Tong L Hsu PW Chang LM Blatt 2011 Evaluation of current treatment recommendations for chronic hepatitis B: a 2011 update J Gastroenterol Hepatol 26 829 835 21214888 1:CAS:528:DC%2BC3MXntlygs7c%3D
71. MF Yuen 2007 Revisiting the natural history of chronic hepatitis B: impact of new concepts on clinical management J Gastroenterol Hepatol 22 973 976 17489961
72. MF Yuen CK Hui CC Cheng CH Wu YP Lai CL Lai 2001 Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications Hepatology 34 139 145 11431745 1:CAS:528:DC%2BD3MXltlKjsL4%3D
73. YF Liaw IS Sheen CM Lee, et al. 2011 Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease Hepatology 53 62 72 21254162 1:CAS:528: DC%2BC3MXitVeksrk%3D
74. Gish R, Tsai N, Pan C, et al. Efficacy and safety of entecavir in nucleos(t)ide Naïve Asians with HBeAg-positive and -negative chronic hepatitis B: results from studies ETV-022/027. Presented at the 61st Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA. October 30-November 3; 2010: Abstract No. 485.
75. YF Liaw JJ Sung WC Chow, et al. 2004 Lamivudine for patients with chronic hepatitis B and advanced liver disease N Engl J Med 351 1521 1531 15470215 1:CAS:528:DC%2BD2cXot1Kls7w%3D
76. JH Shim HC Lee KM Kim, et al. 2010 Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis J Hepatol 52 176 182 20006394 1:CAS:528:DC%2BC3cXhs1art74%3D
77. SH Han FA Durazo S Saab MJ Tong 2011 A proposed, evidence-based approach to the treatment of chronic Hepatitis B J Clin Gastroenterol 45 259 266 20856136
78. G Fattovich 2003 Natural history and prognosis of hepatitis B Semin Liver Dis 23 47 58 12616450 (Pubitemid 36254662)
79. CJ Liu BF Chen PJ Chen, et al. 2006 Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case-control study J Infect Dis 194 594 599 16897657 1:CAS:528:DC%2BD28XpvFejtr4%3D
80. YF Liaw 2009 Natural history of chronic hepatitis B virus infection and long-term outcome under treatment Liver Int 29 100 107 19207972
81. N Leung 2008 Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues Hepatol Int 2 163 178 19669301 (Pubitemid 351650144)
82. TT Chang CL Lai RN Chien, et al. 2004 Four years of lamivudine treatment in Chinese patients with chronic hepatitis B J Gastroenterol Hepatol 19 1276 1282 15482535 1:CAS:528:DC%2BD2cXhtVKnt7vJ
83. AS Lok CL Lai N Leung, et al. 2003 Long-term safety of lamivudine treatment in patients with chronic hepatitis B Gastroenterology 125 1714 1722 14724824 1:CAS:528:DC%2BD2cXhtVOrug%3D%3D (Pubitemid 37500436)
84. HL Chan H Wang J Niu AM Chim JJ Sung 2007 Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial Antivir Ther 12 345 353 17591024 1:CAS:528: DC%2BD2sXntFOrsbc%3D (Pubitemid 46787979)
85. MG Peters H Hann Hw P Martin, et al. 2004 Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B Gastroenterology 126 91 101 14699491 1:CAS:528:DC%2BD2cXhtFGntLo%3D (Pubitemid 38040727)
86. SG Lim P Marcellin N Tassopoulos, et al. 2007 Clinical trial: effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B Aliment Pharmacol Ther 26 1419 1428 17983369 1:CAS:528: DC%2BD1cXitlyl (Pubitemid 350045604)
87. SJ Hadziyannis NC Tassopoulos EJ Heathcote, et al. 2006 Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years Gastroenterology 131 1743 1751 17087951 1:CAS:528:DC%2BD2sXhtFyltLs%3D (Pubitemid 44958517)
88. YF Liaw E Gane N Leung, et al. 2009 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B Gastroenterology 136 486 495 19027013 1:CAS:528:DC%2BD1MXislOhtLs%3D
89. J Hou YK Yin D Xu, et al. 2008 Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial Hepatology 47 447 454 18080339 1:CAS:528:DC%2BD1cXitF2ltbc%3D (Pubitemid 351280712)
90. P Marcellin GK Lau F Bonino, et al. 2004 Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B N Engl J Med 351 1206 1217 15371578 1:CAS:528: DC%2BD2cXns12rsr0%3D (Pubitemid 39296307)
91. GK Lau T Piratvisuth KX Luo, et al. 2005 Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B N Engl J Med 352 2682 2695 15987917 1:CAS:528:DC%2BD2MXls1SktL8%3D (Pubitemid 41007823)
92. T Piratvisuth G Lau YC Chao, et al. 2008 Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B Hepatol Int 2 102 110 19669285 (Pubitemid 351250409)
93. TT Chang RG Gish R de Man, et al. 2006 A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B N Engl J Med 354 1001 1010 16525137 1:CAS:528:DC%2BD28XitFWms7Y%3D (Pubitemid 43357804)
94. Seto WK, Lai C-L, Fung J, et al. Three-year study on viral suppression and resistance profile for treatment-naive CHB patients receiving continuous entecavir treatment. Presented at the 20th Conference of the Asian Pacific Association for the Study of the Liver, Beijing, China; March 25-28 2010. FP-095.
95. G Yao 2007 Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China J Antimicrob Chemother 60 201 205 17556353 1:CAS:528:DC%2BD2sXos12mtr0%3D (Pubitemid 47243868)
96. Pan C, Tong MJ, Kowdley K, et al. Long-term Entecavir treatment for up to 5 years in Asians with HBeAg-positive nucleos(t)ide-naive chronic hepatitis B: results from ETV-022 and -901. Presented at the 61st Annual Meeting of the American Association for the Study of Liver Diseases. Boston MA; November 2010: Abstract no. 478.
97. Tong MJ, Chang TT, Wu SS, et al. Histologic improvement in Asian patients with HBeAg(+) and HBeAg(-) chronic hepatitis B after long-term treatment with entecavir: results from ETV-022, -027 and -901 studies. Presented at Digestive Disease Week 2010. New Orleans, LA; May 2010: Abstract no. 433.
98. Tenney DJ, Pokornowski KA, Rose RE, et al. Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naive patients. Presented at the 60th Annual Meeting of the American Association for the Study of Liver Diseases. San Francisco, CA; November 2009: Abstract no. 20.
99. Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL. Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am J Gastroenterol. 2011.
100. Pan C, Hu KQ. Excellent treatment response to tenofovir (TDF) monotherapy in chronic hepatitis B (CHB) patients with prior suboptimal response to entecavir (ETV) monotherapy. Presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA; November 2008: Abstract no. 932.
101. Lee S, Heathcote EJ, Sievert W, et al. Tenofovir disoproxil fumarate (TDF) versus adefovir dipivoxil (ADV) in Asians with HBeAg-positive and HBeAg-negative chronic hepatitis B participating in studies 102 and 103. Presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA; November 2008: Abstract no. 980.
102. Gane E, Lee S, Heathcote EJ, et al. Four years efficacy and safety of tenofovir disoproxil fumarate (TDF) in Asians with HBeAg-positive and HBeAg-negative chronic hepatitis B (CHB), preliminary analysis. Presented at the 61st Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA; November, 2010: Abstract number 481.
103. Pan C, Chan S, Trinh H, et al. Tenofovir disoproxil fumarate (TDF) shows similar virologic suppression and safety between Asians and Non-Asians with chronic hepatitis B (CHB). Presented at the 21st Conference of the Asian Pacific Association for the Study of the Liver, Bangkok, Thailand; February 18, 2011: Abstract no. PP05-99.
104. Genentech, Inc. PEGASYS (peginterferon alfa-2a) full prescribing information; 2011. http://www.gene.com/gene/products/information/pegasys/pdf/pi. pdf. Accessed April 16, 2011.
105. ® (adefovir dipivoxil) tablets full prescribing information; 2009. http://www.hepsera.com/. Accessed April 16, 2011.
106. ® (tenofovir disoproxil fumarate) tablets Full Prescribing Information. 2010; http://www.viread.com/ global-pdfs/Viread-FPI.pdf. Accessed April 16, 2011.
107. RJ Fontana 2009 Side effects of long-term oral antiviral therapy for hepatitis B Hepatology 49 S185 S195 19399802 1:CAS:528:DC%2BD1MXlvFKqsb4%3D
108. EB Keeffe S Zeuzem RS Koff, et al. 2007 Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B Clin Gastroenterol Hepatol 5 890 897 17632041 (Pubitemid 47127032)
109. Pan C, Hu KQ, Yu A, Chen W, Bunchorntavakul C, Reddy R. Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir. J Viral Hepat. 2011 (in press).
110. YH Kuo CH Chen JH Wang, et al. 2010 Extended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversion Scand J Gastroenterol 45 75 81 20030580 1:CAS:528:DC%2BD1MXhs1aqt7jF
111. JG Reijnders MJ Perquin N Zhang BE Hansen HL Janssen 2010 Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B Gastroenterology 139 491 498 20381492 1:CAS:528:DC%2BC3cXpsVGnu7s%3D
112. Fung J, Lai CL, Tanaka Y, et al. The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion. Am J Gastroenterol. 2009;104:1940-1946; quiz 1947.
113. SJ Hadziyannis V Sevastianos IN Rapti N Tassopoulos 2006 Sustained biochemical and virological remission after discontinuation of 4 to 5 years of adefovir dipivoxil (ADV) treatment in HBeAg-negative chronic hepatitis B Hepatology 44 231A
114. MF Yuen T Kato M Mizokami, et al. 2003 Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations J Hepatol 39 850 855 14568270 1:CAS:528:DC%2BD3sXotVert7k%3D (Pubitemid 37372197)
115. S Nafa S Ahmed D Tavan, et al. 2000 Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B Hepatology 32 1078 1088 11050059 1:STN:280:DC%2BD3M%2FivFagsQ%3D%3D
116. D Mutimer D Pillay P Shields, et al. 2000 Outcome of lamivudine-resistant hepatitis B virus infection in the liver transplant recipient Gut 46 107 113 10601065 1:STN:280:DC%2BD3c%2FmvFGisg%3D%3D (Pubitemid 30307687)
117. V Thibault C Aubron-Olivier H Agut C Katlama 2002 Primary infection with a lamivudine-resistant hepatitis B virus AIDS 16 131 133 11741175 (Pubitemid 34062194)
118. C Hongthanakorn W Chotiyaputta K Oberhelman, et al. 2011 Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice Hepatology 53 1854 1863 21618260
119. SJ Patterson J George SI Strasser, et al. 2011 Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B Gut 60 247 254 21036792 1:CAS:528: DC%2BC3MXitlemurg%3D
120. JG Reijnders K Deterding J Petersen, et al. 2010 Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues J Hepatol 52 493 500 20185191 1:CAS:528:DC%2BC3cXjvFKmsLg%3D
121. WH Choe SP Hong BK Kim, et al. 2009 Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir Antivir Ther 14 985 993 19918102 1:CAS:528: DC%2BD1MXhsFKjtLnK
122. Nguyen MH, Trinh HN, Do ST, et al. Response to entecavir (ETV) in patients with chronic hepatitis B (CHB) and prior suboptimal response to adefovir (ADV): interim report of a multicenter study. Gastroenterology. 2009;136:A-798.
123. CQ Pan KQ Hu 2008 Excellent treatment response to tenofovir monotherapy in chronic hepatitis B (CHB) patients with prior suboptimal response to entecavir monotherapy Hepatology 8 725A
124. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006;55(RR-16):1-33; quiz CE31-34.
125. WM Xu YT Cui L Wang, et al. 2009 Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study J Viral Hepat 16 94 103 19175878
126. E Wiseman MA Fraser S Holden, et al. 2009 Perinatal transmission of hepatitis B virus: an Australian experience Med J Aust 190 489 492 19413519
127. Zou H, Chen Y, Duan Z, Zhang H, Pan CQ. Virologic factors associated with failure to passive active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat. (in press).
128. CQ Pan GR Han W Zhao HX Jiang MK Cao 2010 A prospective open-label study to evaluate the efficacy, safety and tolerability of telbivudine in HbeAg+ chronic hepatitis B pregnant women Hepatology 52 500A
129. GR Han W Zhao HX Jiang MK Cao HX Jiang CQ Pan 2010 A prospective open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus to the infant Hepatology 52 427A
130. H Zhou Y Chen Z Duan H Zhang CQ Pan 2010 A prospective study for clinical outcomes of caesarean section on perinatal transmission of hepatitis B virus in infants born to HBeAg-positive mothers with chronic hepatitis B Hepatology 52 441A
131. JH Hung CJ Chu PL Sung, et al. 2008 Lamivudine therapy in the treatment of chronic hepatitis B with acute exacerbation during pregnancy J Chin Med Assoc 71 155 158 18364269 1:CAS:528:DC%2BD1cXmtFKksbo%3D
132. Z Abbas W Jafri S Raza 2010 Hepatitis D: scenario in the Asia-Pacific region World J Gastroenterol 16 554 562 20128022
133. CJ Liu JM Liou DS Chen PJ Chen 2005 Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections J Formos Med Assoc 104 783 791 16496056
134. H Wedemeyer 2011 Hepatitis D revival Liver Int Official J Int Assoc Study Liver 31 140 144
135. CJ Chu SD Lee 2008 Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment J Gastroenterol Hepatol 23 512 520 18397482
136. JW Yu LJ Sun YH Zhao P Kang J Gao SC Li 2009 Analysis of the efficacy of treatment with peginterferon alpha-2a and ribavirin in patients coinfected with hepatitis B virus and hepatitis C virus Liver Int Official J Int Assoc Study Liver 29 1485 1493 1:CAS:528:DC%2BD1MXhtlGgtb%2FJ
137. Liu CJ, Chuang WL, Lee CM, et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology. 2009;136:496-504 e493.
138. GK Nikolopoulos D Paraskevis E Hatzitheodorou, et al. 2009 Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis Clin Infect Dis 48 1763 1771 19435436
139. CL Thio 2009 Hepatitis B and human immunodeficiency virus coinfection Hepatology 49 S138 S145 19399813
140. L Martin-Carbonero T Teixeira E Poveda, et al. 2011 Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues AIDS 25 73 79 21076274
141. MA McMahon BL Jilek TP Brennan, et al. 2007 The HBV drug entecavir-effects on HIV-1 replication and resistance N Engl J Med 356 2614 2621 17582071 1:CAS:528:DC%2BD2sXmslKjs7o%3D (Pubitemid 46961006)
142. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2011; 1-166. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed April 17, 2011.
143. V Soriano M Puoti M Sulkowski, et al. 2007 Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel AIDS 21 1073 1089 17502718 (Pubitemid 46763278)
144. C Manegold C Hannoun A Wywiol, et al. 2001 Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy Clin Infect Dis 32 144 148 11118394 1:CAS:528:DC%2BD3MXnsVSluw%3D%3D (Pubitemid 32150960)
145. JH Hoofnagle GM Dusheiko DF Schafer, et al. 1982 Reactivation of chronic hepatitis B virus infection by cancer chemotherapy Ann Intern Med 96 447 449 7065560 1:STN:280:DyaL387lvVGrtA%3D%3D (Pubitemid 12139868)
146. JS Lubel PW Angus 2010 Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management J Gastroenterol Hepatol 25 864 871 20546439 1:CAS:528:DC%2BC3cXnvFKgtbo%3D
147. R Loomba A Rowley R Wesley, et al. 2008 Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy Ann Intern Med 148 519 528 18378948 (Pubitemid 351665421)
148. Centers for Disease Control. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR. 2008;57:1-20.
149. M Yamagata T Murohisa K Tsuchida, et al. 2007 Fulminant B hepatitis in a surface antigen and hepatitis B DNA-negative patient with diffuse large B-cell lymphoma after CHOP chemotherapy plus rituximab Leuk Lymphoma 48 431 433 17325912 1:CAS:528:DC%2BD2sXjsVKnu7Y%3D (Pubitemid 46994901)
150. M Onozawa S Hashino K Izumiyama, et al. 2005 Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection Transplantation 79 616 619 15753855 (Pubitemid 40365894)
151. AM Evens BD Jovanovic YC Su, et al. 2011 Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports Ann Oncol 22 1170 1180 21115603 1:STN:280:DC%2BC3Mvmtlyjuw%3D%3D
152. Lee SS, Heathcote EJ, Sievert W, et al. Three years efficacy and safety of tenofovir disoproxil fumarate (TDF) in Asians with HBeAg-positive and HBeAg-negative chronic hepatitis B. Presented at 60th Annual Meeting of the American Association for the Study of Liver Diseases; October 30-November 3 2009. Boston, MA: Poster no. 490.
153. Chan S, Pan C, Bae H, et al. A phase 4 study to evaluate the efficacy, safety, and tolerability of tenofovir disoproxil fumarate (TDF) in Asian American adults with chronic hepatitis B (CHB) infection. Presented at the 21st Conference of the Asian Pacific for the Study of the Liver. Bangkok, Thailand; February 17-20 2011: Abstract no. 608.
154. T Berg P Marcellin F Zoulim, et al. 2010 Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection Gastroenterology 139 1207 1217 20600025 1:CAS:528:DC%2BC3cXht1CgtrzM